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ABSTRACT
Administration of peginterferon alfa-2b plus ribavirin results in an early hepati-
tis C virus (HCV) RNA decay followed by an increase as the drug concentration declines
between doses. Upon administration of the next dose 1 week later, the same pattern is ob-
served. We have incorporated pharmacokinetic/pharmacodynamic analysis into a model
of viral dynamics to describe the effect that changes in drug concentration and effective-
ness can have on viral levels. To illustrate the relationship between pharmacokinetics and
viral dynamics, we fit the model to data from four HCV/human immunodeficiency virus
co-infected patients, and obtained good agreement with the measured serum HCV RNA
levels. We were able to account for the observed increases in HCV RNA, and estimate
virion and drug half-lives that are in agreement with previous reports. Models incorporat-
ing pharmacokinetics are needed to correctly interpret viral load changes and estimate
drug effectiveness in treatment protocols using peginterferon alfa-2b.
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The delayed clearance of peginterferon alfa-2b
(PEG-IFN alfa-2b) from the body allows it to be dosed
once weekly in HCV patients, less frequently than the
usual dosing of three times a week for standard IFN
alfa.1,2 While once-weekly dosing results in greater con-
venience for patients, it leads to decreases in drug con-
centration between doses, resulting in decreases in effi-
cacy and increases in viral load as drug concentrations
drop.3 The effects of the decrease in drug concentration
on HCV RNA have not been explored. Explanation of
the interplay among these phenomena requires a combi-
nation of pharmacokinetic, pharmacodynamic, and viral
dynamic models. In this article, we illustrate these prin-
ciples and present a new theoretical framework to de-
scribe the antiviral effectiveness of treatment with PEG-
IFN alfa-2b plus ribavirin.
VIRAL LOAD DURING TREATMENT WITH
PEGYLATED INTERFERON ALFA-2B
We conducted a preliminary analysis of 4 HCV-infected
patients treated with 1.5 µg/kg PEG-IFN alfa-2b (12
kDa) once weekly plus daily ribavirin (13 mg/kg) for 28
days. Three of the 4 patients were male, 3 were infected
with genotype 1a and one with genotype 2, 2 patients
were White, one was Hispanic, and one was African
American (Table 1).The average patient age was 51 years,
and average baseline weight was 86 kg (Table 1). These
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Table 1 Patient Demographics
Age Weight HCV
Patient (years) Sex Race (kg) Genotype
1 56 M Caucasian 81.7 1a
2 46 M Hispanic 88.9 1a
3 48 F African-American 81.6 1a
4 52 M Caucasian 93.4 2
Average (±SD) 50.5 ± 4.4 86.4 ± 5.8
patients were also co-infected with human immunode-
ficiency virus (HIV)-1 and had HIV-1 RNA levels below
the limit of detection of 400 copies/mL. Serum HCV
RNA was measured when the first, second, third, and
fifth doses were given, and at regular intervals between
doses. We analyzed the viral dynamics during the first
week, when sampling was most frequent: at baseline, at
6 and 12 hours after baseline, and on days 1, 2, 3, 5, 6,
and 7 after baseline. In patient #3, no measurements were
taken on days 2 and 3, but a measurement was taken on
day 4.
The intensive sampling schedule around the
weekly doses of PEG-IFN alfa-2b allowed the charac-
terization of HCV dynamics as the serum concentration
of PEG-IFN alfa-2b peaked and waned.3 In most pa-
tients, there was an initial fast pronounced decline in
HCV RNA following the first dose, the same as had
been observed in previous studies of HCV treatment.4–8
A few days after the first dose, most of the patients ex-
hibited a rebound in HCV RNA (Fig. 1). We hypothe-
size that this rebound resulted from a decline in drug
levels and, consequently, in drug effectiveness.
MODELING OF VIRAL DYNAMICS
The Neumann et al4 model of viral dynamics is described
by the following set of differential equations for infected
cells and free virus:
Figure 1 Evolution of serum HCV RNA levels during successive administration of PEG-IFN alfa-2b injections in 4 individuals in-
fected with HCV and HIV.
MODELING HCV TREATMENT WITH PEG-IFN/POWERS ET AL 15
Table 2 Parameter Estimates from Fitting the Elimination-Only Model
V0  c ke t0
Patient (106 IU/mL) (day1) (day1) max min (day1) (days)
1 1.39 0.37 4.20 0.99 0.03 1.11 0.50
2 3.34 0.25 5.39 0.98 0.02 1.10 0.25
3 2.34 0.02 1.76 0.89 0.07 0.66 0.00
4 12.8 0.45 9.16 0.98 0.63 0.45 0.64
Average (±SD) 5.0 ± 5.3 0.3 ± 0.2 5.1 ± 3.1 0.96 ± 0.05 0.2 ± 0.3 0.8 ± 0.3 0.4 ± 0.3
The virion production rate, p, was fixed at 10 virions/cell/day for all patients. V0 and t0 were estimated from fits of HCV
RNA to Equation 2.
dI /dt = VT  I (1)
dV/dt =(1ε(t)) pIcV
In this system, the free virus, V, infects uninfected
hepatocytes (the VT term), thereby generating infected
cells, I, that subsequently produce virus at rate p per cell.
The virus is cleared with rate constant c and infected
cells are lost at rate  per cell. PEG-IFN alfa-2b is as-
sumed to block a fraction, ε(t), of the production of virus
from infected cells but not to affect virion or infected
cell clearance rates. To solve these equations, we assume
that the number of uninfected cells, T, remains approxi-
mately constant during therapy.
When drug effectiveness is constant, that is,
ε(t)=ε, these equations can be solved to yield the solu-
tion, Equation 2, which predicts that viral load V(t) will
decrease with (time on therapy, t.
V(t) = 1 V0[1  c +   2ce1(tt0) + (2)2 
1 + c +   2ce2(tt0) ],
where
1 = 0.5(c +  + ), 2 = 0.5(c +   ), and
 = √(c  )2 + 4(1  )c.
If c >> , then 1 ~ c and 2 ~ε, corresponding to
the first and second phase slopes observed when ln V(t)
is plotted against t. Additionally, the virus is initially as-
sumed to be in steady state, so that V0 represents a con-
stant baseline amount of HCV RNA. The parameter t0
describes the delay usually observed between the ad-
ministration of IFN and its effect in blocking virion
production, which causes the initial decline in viral
load. When a delay is present, Equation 2 is valid fol-
lowing the delay (i.e., for t > t0), and for t < t0, V(t) = V0.
While V0 and t0 can be roughly estimated directly from
the data, here we used nonlinear least-squares regres-
sion analysis to fit the first 7 days of viral load data to
Equation 2 to estimate V0 and t0. These values (Table 2)
were used in the analyses that follow.
Modeling of Pharmacokinetics—
Elimination-Only Model
While Equation 2 has been shown to accurately fit viral
load data obtained when patients are treated daily with
high-dose standard IFN,4–6 it is not appropriate to de-
scribe the changes in viral load when PEG-IFN alfa-2b
is given once weekly. With once-weekly dosing there
appears to be a reduction in the drug’s effectiveness in
blocking viral production due to a decline in its concen-
tration between doses,3 and hence the assumption of
constant drug effectiveness no longer applies. If we as-
sume that after the delay t0, the concentration of PEG-
IFN alfa-2b simply decays exponentially, the drug con-
centration, C, over time can be described by
C(t) = C0eke(tto), (3)
where C0 is the drug concentration at time t0 and ke is the
rate constant for drug elimination. Because effectiveness
can be assumed to depend on drug concentration as9
(t) = C(t) (4)
IC50 + C(t) 
,
where IC50 is the concentration at which the drug’s ef-
fectiveness is half its maximum, the decay in drug con-
centration described in Equation 3 leads to a decrease in
effectiveness. Simulated changes in drug concentration
and effectiveness, as predicted by this model, are dis-
played in Figure 2, where we assume that Equation 4 is
valid for t > t0.
Equations 3 and 4 were incorporated into Equa-
tion 1 to create a new model for viral load change under
PEG-IFN alfa-2b treatment. The delay t0 is interpreted
as comprising both the time for the drug level to rise
following injection as well as the biological delay be-
tween IFN binding to its cellular receptor and the anti-
viral response of the infected cell. Using nonlinear least-
squares regression analysis, data from the first 7 days of
treatment were fitted to this “elimination-only model”
(Fig. 3). Values for the parameters c, , C0 /IC50, and ke
were estimated, and the maximum effectiveness, that is,
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A B
Figure 2 Simulated concentration and efficacy profiles with once-weekly dosing. Delays are not illustrated. Parameter values used
in the simulations were: ka = 1.9 d1, ke = 1.0 d1, Dose = 129 µg, IC50 = 30.96 pg/mL, C0 = 750 pg/mL, and F/Vd = 0.012 L1.
(A) Drug concentration over time; elimination-only model (black) and absorption and elimination model (grey). (B) Drug efficacy over
time; elimination-only model (black) and absorption and elimination model (grey).
Figure 3 HCV RNA according to the elimination-only model. Best-fit solutions (solid line) of the model, Equations (1) – (4), to ex-
perimental data (●) from 4 patients during the first 7 days of treatment.
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εmax= (C0 /IC50 )/[1 + (C0 /IC50 )], was calculated (Table
2). The corresponding average virion and drug half-lives
(± SD) were 4.6 ± 3.4 hours and 23.0 ± 10.4 hours, re-
spectively, consistent with previously published values.1,4
Virion production was blocked by PEG-IFN alfa-2b
with an average maximum effectiveness (εmax) of 96%.
In Table 2, we also show the estimated drug efficacy 7
days after the first dose, that is, εmin= (C0 /IC50)(e7ke)/[1
+ (C0 /IC50)(e7ke)], just before the second weekly PEG-
IFN dose. In 3 of the 4 patients studied, this residual ef-
fectiveness is very low (< 10%). In P4, the effectiveness
even one week post-injection is 63% and, as Figure 3 il-
lustrates, P4 was the only patient who did not show an
increase in viral load during the week. It is noteworthy
that this patient was infected with genotype-2 HCV, for
which a higher effectiveness of normal IFN alfa has been
reported.5
Modeling of Pharmacokinetics—
Absorption and Elimination Model
The “elimination-only model” used above, while simple,
does not adequately describe the absorption of drug from
the site of subcutaneous injection into the blood and liver.
Thus we also conducted analyses with a model that in-
cludes both absorption and elimination of PEG-IFN
alfa-2b in the blood.9
This “absorption and elimination model” describes
the change in the amount of drug in the blood (A) as
follows:
dA = ka X  ke A, (5)dt
where X is the amount of drug at the absorption site, ka
is the rate of absorption, and ke is the rate of elimina-
tion. X can be further characterized as X = FDekat,
where F is the bioavailability (the extent to which the
active drug enters systemic circulation) and D is the drug
dose. The solution to Equation 5 gives an expression for
the amount of drug in the blood over time, A(t), and by
dividing this expression by the volume of distribution,
Vd, we obtain the following equation for the concentra-
tion of drug in the blood:
C(t) =
ka FD ekat  eket , (6)(ke  ka)Vd
following a single injection at time t = 0. More complex
expressions are needed when the drug is given multiple
times. Again, changes in drug concentration affect ef-
fectiveness; however, to incorporate the effects of a delay
between PEG-IFN alfa-2b binding its receptor and be-
ginning its biological action, we assume that the effec-
tiveness at time t depends on the drug concentration at
time t  , that is, there is a delay of length  between a
cell sensing an IFN concentration C(t) and responding
to it. Thus, for t > ,
ε(t) = C(t  ) (7)
IC50 + C(t  ) 
.
Simulated changes in concentration and effective-
ness with this model, as described by Equations 6 and 7,
are displayed in Figure 2. The absorption and elimination
model (Equations 1, 6, and 7) was also fitted to data over
the first 7 days of therapy and gave fits comparable to
those shown in Figure 3 (data not shown). Conceptually,
this model has an advantage over the elimination-only
model in that it fully separates pharmacokinetic effects
from the delays intrinsic to the interferon response. How-
ever, it is more complicated mathematically, has an addi-
tional parameter, and requires software specially designed
to analyze delay-differential equations.
SUMMARY
Administration of PEG-IFN alfa-2b plus ribavirin results
in early HCV RNA decays in HIV-HCV co-infected
patients, followed by viral load increases as the drug
concentration and efficacy decline between doses.
When the next dose is administered 1 week later, the
same pattern is observed. We have used two pharmaco-
kinetic models—one that includes drug elimination
only and one that considers both absorption and elimi-
nation—to describe changes in concentration and drug
effectiveness in blocking virion production during early
therapy with PEG-IFN alfa-2b (12 kDa). We have in-
corporated each of these pharmacokinetic models into
the Neumann et al4 model of viral dynamics to describe
the effect that changes in drug concentration and effec-
tiveness can have on HCV RNA. In this initial model-
ing study we did not consider the pharmacokinetics of
ribavirin because the drug is administered twice daily.
Analyzing data from 4 patients, we obtained good
agreement between the models and the measured viral
load data, were able to account for the observed in-
creases in HCV RNA, and generated estimates of drug
effectiveness in blocking virion production. In contrast
to our previous work,4 we found that effectiveness is not
a constant but changes with time, having a maximum
and then decaying until the subsequent dose. Our re-
sults suggest that without the modifications suggested
here, the Neumann et al4 model—with its assumption
of fixed drug effectiveness—is not appropriate for the
analysis of treatment data obtained with PEG-IFN
alfa-2b. As these preliminary findings are based on data
from only 4 patients, subsequent analyses in larger pa-
tient cohorts are warranted to further our understand-
ing of the pharmacokinetics and viral dynamics in pa-
tients receiving PEG-IFN alfa-2b.
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